Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)
- no estimate extracted1 study · 80 participantsVery low
Oral propranolol showed no clear difference in adverse events experienced at short or long term ‐ Serious adverse… compared with placebo (low certainty).
Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
Fexofenadine 120 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (1‐week intervention) (moderate certainty).
Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).
Cetirizine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).